Value through Innovation23 October 2014
03 February 2012

Boehringer Ingelheim, GWT and the TU Dresden sign diabetes research collaboration

Ingelheim, Dresden February 3rd, 2012 – Boehringer Ingelheim, GWT and the Department of Medicine of the TU Dresden have signed a research collaboration agreement to develop new insights into the causes of diabetes and the link between excessive blood glucose, the hallmark of diabetes, and the serious complications of the disease that can affect many organ functions.

As partners, Boehringer Ingelheim, GWT and the TU Dresden will work together to enhance the knowledge of the disease to ultimately enable the discovery and development of innovative therapies that will treat these diseases more effectively. With this five-year industry-academia collaboration, Boehringer Ingelheim will further strengthen its efforts to translate basic scientific findings into more effective treatments of human diseases.

The partners have initially defined six research projects bridging between preclinical findings in the laboratory or from investigational treatments, to the corresponding clinical situation with patients. The projects range from the exploration of causes for the destruction of insulin-producing beta cells to the cells and molecules triggering diabetic complications in organs such as the eye (diabetic retinopathy), which can lead to blindness, kidney (nephropathy), nerves (neuropathy) or skin (ulcerations). Results from these studies may help to design new medicines for clinical testing, or to better understand how drug candidates can be tested in clinical trials with biomarkers, and ultimately used in an optimal way for those patients most likely to show clinical benefit.

“We are very pleased to collaborate in this important field of medical need with the distinguished scientists of the TU Dresden”, says Professor Wolfgang Rettig, the Senior Vice President of Research at Boehringer Ingelheim. “This research partnership builds upon the excellent, shared experience gained from our earlier collaboration with the TU Dresden.”

“Our academic industry partnership with Boehringer Ingelheim and the TU Dresden is ideally suited to move forward the translational process from bench to bedside”, says Professor Stefan Bornstein, Director of the Medical Clinic and Policlinic III of the University Clinic Carl Gustav Carus Dresden.

About the Dresden Diabetes Research Centre
The Medical Clinic and Policlinic III of the University Clinic Carl Gustav Carus Dresden, led by Professor Stefan Bornstein, is one of the leading diabetes research centres in Germanywith 30,000 patients treated annually. The clinic successfully launched an islet cell transplant program for the treatment of diabetes type 1 and also offered the first professorship for the research of prevention and care of diabetes in Europe. In cooperation with the Paul-Langerhans-Institut at the Dresden University hospital - one of the German center for diabetes research (DZD) – new therapies are explored.
For more information see www.uniklinikum-dresden.de/mk3

About Boehringer Ingelheim
The Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 145 affiliates and more than 42,000 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine.

As a central element of its culture, Boehringer Ingelheim pledges to act socially responsible. Involvement in social projects, caring for employees and their families, and providing equal opportunities for all employees form the foundation of the global operations. Mutual cooperation and respect, as well as environmental protection and sustainability are intrinsic factors in all of Boehringer Ingelheim’s endeavors.

In 2010, Boehringer Ingelheim posted net sales of about 12.6 billion euro while spending almost 24% of net sales in its largest business segment Prescription Medicines on research and development. Updated information on the corporation’s annual results in 2011 will be available end of April 2012.

About GWT
The GWT-TUD is a company of the TUDAG-Group, the Technische Universität Dresden AG. The company is a service provider for knowledge and technology transfers and creates solutions for concrete projects and questions raised in research and development for clients in the industry.
By the temporary use of high performing interdisciplinary research teams of the GWT the clients professional staff can be supported and the scope of innovative endeavors can be individually designed with the benefit of no need to increase own resources.
With more than 1.000 individual projects and a total overall result of more than 18 million Euros the GWT-TUD GmbH belongs to the leading organizations for knowledge and technology transfers in Germany.
For more information please visit www.gwtonline.de

Media contact

  • Julia Meyer-Kleinmann
    Boehringer Ingelheim

    Media & PR
    Julia Meyer-Kleinmann
    Binger Strasse 173
    55216 Ingelheim am Rhein
    GERMANY

Konrad Kästner M.A.
Referent Öffentlichkeitsarbeit und Marketing
Technische Universität Dresden
Medizinische Fakultät Carl Gustav Carus
Dekanat
01062 Dresden
Tel.: +49 (351) 458-5486
Fax: +49 (351) 449 210 506
E-Mail: konrad.kaestner@tu-dresden.de

Media contact

  • Julia Meyer-Kleinmann
    Boehringer Ingelheim

    Media & PR
    Julia Meyer-Kleinmann
    Binger Strasse 173
    55216 Ingelheim am Rhein
    GERMANY